Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

The clinical benefit of therapeutic cancer vaccines has been established. Whereas
regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in …

Hepatitis B virus (HBV) infection causes chronic hepatitis and has long term complications.
Individuals ever infected with HBV are at risk of viral reactivation under certain …

Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million
people worldwide. While treatment for HBV has improved, HBV patients often require …

Through specific interactions with distinct types of Fcγ receptors (FcγRs), the Fc domain of
immunoglobulin G (IgG) mediates a wide spectrum of immunological functions that influence …

“Functional cure” is being pursued as the ultimate endpoint of antiviral treatment in chronic
hepatitis B (CHB), which is characterized by loss of HBsAg whether or not anti-HBs …

Efficacy and safety of recombinant yeast-derived hepatitis B vaccines for prevention of
hepatitis B have been demonstrated unequivocally worldwide as reflected in reduction in …

While new therapies for chronic hepatitis C virus infection have delivered remarkable cure
rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal …